



This press release may not be distributed in the United States, Canada, Australia or Japan. This press release is not offering material and is for information purposes only.

Theraclion raises €4 million in a private placement from leading European and US institutional investors

Malakoff – June 17, 2015 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, has today announced that it has raised €4 million in a private placement with leading European and US institutional investors. The transaction was completed in accordance with Article L. 411-2 II of the French Monetary and Financial Code.

In connection with the private placement, Theraclion issued 495,938 new shares for a total of €3,967,504 under a capital increase with elimination of pre-emptive subscription rights, pursuant to the 17th Resolution approved by the Extraordinary General Meeting of April 28, 2015. The number of these new shares represents 13% of the number of shares currently in circulation, bringing the total number of shares after the issue to 4,276,941.

The price of the placement was set at €8 per share. The subscription price of each new share is in accordance with the 17th resolution of the Extraordinary General Meeting of the Company of April 28, 2015.

The new shares issued will be fungible with existing shares. They will be listed on the Alternext Paris market on the same listing line as existing shares under code ISIN FR0010120402. Settlement-delivery took place today.

This capital increase was executed with leading institutional investors in Europe, including existing investor, Truffle Capital, and the United States.

This private placement will support Theraclion in:

- growing sales in Europe;
- the continued development of the Echopulse probe® in existing and new indications;
- obtaining approval for Echopulse® in the United States and China.

“The success of this capital increase clearly demonstrates the confidence of our existing shareholders, as well as those new investors who participated in this private placement, in particular in Germany and the US. This transaction provides us with the funds needed to continue the development of our

innovative echotherapy solution, the Echopulse®, in order to offer a safer, non-invasive treatment to a growing number of patients and in multiple new indications. In addition, we are continuing to grow sales in Europe and internationally, in line with our recently launched marketing strategy," commented David Caumartin, Theraclion's Chief Executive Officer.

Nfinance Securities acted as bookrunner for this placement, and LifeSci Capital acted as the US placement agent. Lexelians provided French legal advice and Mr. Lee Neumann provided US legal advice.

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 25 people, 52 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.

Theraclion is listed on Alternext Paris

PEA-PME Eligible

Mnemonic: ALTHE - ISIN Code: FR0010120402



Disclaimer

This press release and the information it contains does not constitute and shall not be considered as constituting a public offer, an offer to subscribe or an intention to solicit the interest of the public for a public offering of Theraclion securities in France, the United States or any other jurisdiction. In France, the offer of Theraclion shares described above will take place solely as a private placement, in accordance with Article L. 411-2 of the *"Code monétaire et financier"* and applicable regulations. The offering does not constitute a public offering in France, as defined in Article L. 411-1 of the *"Code monétaire et financier"* and no prospectus reviewed or approved by the *Autorité des marchés financiers* will be published.

With respect to Member States of the European Economic Area that have transposed the European Directive 2003/71/EC of the European Parliament and European Council (as amended in particular by Directive 2010/73/EU to the extent that the said Directive has been transposed into each Member State of the European Economic Area), no action has been taken or will be taken to permit a public offering of the securities referred to in this press release requiring the publication of a prospectus in any Member State.

This press release does not constitute and should not be considered to be an offer of securities for sale in the United States. Theraclion does not intend to register securities or conduct a public offering in the United States under the US Securities Act of 1933, as amended. The securities may not be offered or sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended.

This press release may not be distributed in the United States, Canada, Australia or Japan.

Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.

Contacts:

Theraclion

David Caumartin

CEO

Tel.: +33 (0)1 55 48 90 70

david.caumartin@theraclion.com

NewCap

Financial Communications & Investors relations

Emmanuel Huynh / Valentine Brouchet

Tel.: +33 (0)1 44 71 94 94

theraclion@newcap.fr

ALIZE RP

Press Relations

Caroline Carmagnol / Valentine Boivin

Tel.: + 33 (0)1 44 54 36 63

theraclion@alizerp.com